Published : Jun-2020
No. of Pages : 48
1.1 List of Tables
1.2 List of Figures
2 Amyloidosis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of AL Amyloidosis
3.4.4 Diagnosed Prevalent Cases of AL Amyloidosis
3.4.5 Diagnosed Incident Cases and Prevalent Cases of AL Amyloidosis by Subtypes
3.4.6 Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
3.4.7 Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
3.4.8 Diagnosed Incident Cases of ATTR-h
3.4.9 Diagnosed Incident Cases of ATTR-wt and AA Amyloidosis
3.4.10 Diagnosed Prevalent Cases of ATTR-h, ATTR-wt, and AA Amyloidosis
3.4.11 Diagnosed Prevalent Cases of ATTR-h by Those Who Underwent Liver Transplantation
3.5 Epidemiological Forecast for Amyloidosis, 2019-2029
3.5.1 Diagnosed Incident Cases of AL Amyloidosis
3.5.2 Sex-Specific Diagnosed Incident Cases of AL Amyloidosis
3.5.3 Age-Specific Diagnosed Incident Cases of AL Amyloidosis
3.5.4 Diagnosed Incident Cases of AL Amyloidosis by Subtypes
3.5.5 Diagnosed Prevalent Cases of AL Amyloidosis
3.5.6 Sex-Specific Diagnosed Prevalent Cases of AL Amyloidosis
3.5.7 Age-Specific Diagnosed Prevalent Cases of AL Amyloidosis
3.5.8 Diagnosed Prevalent Cases of AL Amyloidosis by Types
3.5.9 Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
3.5.10 Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
3.5.11 Diagnosed Incident Cases of ATTR-h
3.5.12 Diagnosed Prevalent Cases of ATTR-h
3.5.13 Diagnosed Prevalent Cases of ATTR-h Who Underwent Liver Transplantation
3.5.14 Diagnosed Incident Cases of ATTR-wt
3.5.15 Diagnosed Prevalent Cases of ATTR-wt
3.5.16 Diagnosed Incident Cases of AA Amyloidosis
3.5.17 Diagnosed Prevalent Cases of AA Amyloidosis
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
List of Tables
Table 1: Risk Factors and Comorbidities for Amyloidosis
List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of AL Amyloidosis, Both Sexes, All Ages, 2019 and 2029
Figure 2: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, Both Sexes, All Ages, 2019 and 2029
Figure 3: 7MM, Diagnosed Prevalence of AL Amyloidosis, Men and Women, All Ages, 2019
Figure 4: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of AL Amyloidosis
Figure 5: 7MM, Sources Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of AL Amyloidosis by Types
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-h
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h, ATTR-wt, and AA Amyloidosis
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h Underwent Liver Transplantation
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-wt and AA Amyloidosis
Figure 13: 7MM, Diagnosed Incident Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 14: 7MM, Diagnosed Incident Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 15: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 16: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Subtypes, All Ages, Both Sexes, N, 2019
Figure 17: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 18: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 19: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 20: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Types, All Ages, Both Sexes, N, 2019
Figure 21: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages, All Ages, Both Sexes, N, 2019
Figure 22: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma, All Ages, Both Sexes, N, 2019
Figure 23: 7MM, Diagnosed Incident Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 24: 7MM, Diagnosed Prevalent Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 25: 7MM, Diagnosed Prevalent Cases of ATTR-h Who Underwent Liver Transplantation, All Ages, Both Sexes, N, 2019
Figure 26: 7MM, Diagnosed Incident Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 27: 7MM, Diagnosed Prevalent Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 28: 7MM, Diagnosed Incident Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 29: 7MM, Diagnosed Prevalent Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
